Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 740

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006

Open access
Kris, Mark G., Hesketh, Paul J., Somerfield, Mark R., Feyer, Petra, Clark-Snow, Rebecca, Koeller, James M., Morrow, Gary R., Chinnery, Lawrence W., Chesney, Maurice J., Gralla, Richard J., Grunberg, Steven M.·2006·Journal of Clinical Oncology

Abstract

Purpose: To update the 1999 American Society of Clinical Oncology guideline for antiemetics in oncology. Update Methodology: The Update Committee completed a review and analysis of data published from 1998 thru February 2006. The literature review focused on published randomized controlled trials, and systematic reviews and meta-analyses of published phase II and phase III randomized controlled trials. Recommendations: The three-drug combination of a 5-hydroxytryptamine-3 (5-HT 3) serotonin receptor antagonist, dexamethasone, and aprepitant is recommended before chemotherapy of high emetic risk. For persons receiving chemotherapy of high emetic risk, there is no group of patients for whom agents of lower therapeutic index are appropriate first-choice antiemetics. These agents should be reserved for patients intolerant of or refractory to 5-HT 3 serotonin receptor antagonists, neurokinin-1 receptor antagonists, and dexamethasone. The three-drug combination of a 5-HT 3 receptor serotonin antagonist, dexamethasone, and aprepitant is recommended for patients receiving an anthracycline and cyclophosphamide. For patients receiving other chemotherapy of moderate emetic risk, the Update Committee continues to recommend the two-drug combination of a 5-HT 3 receptor serotonin antagonist and dexamethasone. In all patients receiving cisplatin and all other agents of high emetic risk, the two-drug combination of dexamethasone and aprepitant is recommended for the prevention of delayed emesis. The Update Committee no longer recommends the combination of a 5-HT 3 serotonin receptor antagonist and dexamethasone for the prevention of delayed emesis after chemotherapeutic agents of high emetic risk. Conclusion: The Update Committee recommends that clinicians administer antiemetics while considering patients' emetic risk categories and other characteristics.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2006.06.9591

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Cited by

See all 740

Metadata

Authors
Kris, M. G., Hesketh, P. J., Somerfield, M. R., Feyer, P., Clark-Snow, R., Koeller, J. M., Morrow, G. R., Chinnery, L. W., Chesney, M. J., Gralla, R. J., & Grunberg, S. M.
Venue
Journal of Clinical Oncology
Published
2006-06-20
Volume
24
Issue
18
Pages
2932-2947
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2158036326
Cited by
740
References
47
FWCI
76.99
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006. https://app.cochat.ai/papers/10.1200/jco.2006.06.9591
The paper
Kris, M. G., Hesketh, P. J., Somerfield, M. R., Feyer, P., Clark-Snow, R., Koeller, J. M., Morrow, G. R., Chinnery, L. W., Chesney, M. J., Gralla, R. J., & Grunberg, S. M. (2006). American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2006.06.9591

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.